EU/3/18/1992

About

On 21 March 2018, orphan designation (EU/3/18/1992) was granted by the European Commission to argenx BVBA, Belgium, for efgartigimod alfa (also known as ARGX-113) for the treatment of myasthenia gravis.

Key facts

Active substance
Efgartigimod alfa
Disease / condition
Treatment of myasthenia gravis
Date of decision
21/03/2018
Outcome
Positive
Orphan decision number
EU/3/18/1992

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

argenx BVBA
Industriepark Zwijnaarde 7
9052 Gent
Belgium
Tel. +32 9 310 3400
E-mail: info@argenx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating